A Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Obese Children Aged 7 to 11 Years

Inclusion Criteria: * Male or female subjects aged 7-11 years (both inclusive) at the time of signing informed consent * Tanner stage 1 (including subjects with premature adrenarche) at the time of signing informed consent * BMI (body mass index) corresponding to above or equal to 30 kg/m\^2 for adults by international cut-off points (Cole et al 2000)1 and BMI below or equal to 45 kg/m\^2 as well as BMI above or equal to 95th percentile for age and gender Exclusion Criteria: * Subjects with secondary causes of childhood obesity (i.e., hypothalamic, genetic or endocrine causes) * Subjects with confirmed bulimia nervosa disorder * Diagnosis of type 1 diabetes mellitus or type 2 diabetes mellitus as defined by glycosylated haemoglobin (HbA1C) Above or equal to 6.5 % * History of pancreatitis (acute or chronic) * Presence of severe co-morbidities as judged by the investigator * Family or personal history of multiple endocrine neoplasia type 2 (MEN2) or medullary thyroid carcinoma (MTC) * History of major depressive disorder within 2 years before randomisation